A Question of Scale

Premium

This will come as a shock to absolutely nobody, but I'm going to say it anyway: there's nothing straightforward about intellectual property issues. A recent can of worms came in the form of a presentation at a National Academy of Science committee attempting to get to the bottom of gene and protein patents and what kind of impact they have on medicine and research. Debra Leonard, vice chair of laboratory medicine in the department of pathology and laboratory medicine at Weill Medical College of Cornell University, gave a compelling presentation against the current status of gene patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.